ModifiedCignaPolicy 0534

Hematopoietic Stem Cell Transplantation (HSCT) for Solid Tumors

Defines medical necessity and coverage criteria for autologous and allogeneic hematopoietic stem cell transplantation (HSCT) in adults and pediatrics with various solid tumor indications for Cigna-administered benefit plans.

Policy Summary

PayerCigna

PolicyHematopoietic Stem Cell Transplantation (HSCT) for Solid Tumors

Policy CodePolicy 0534

Change TypeRevisions and removal of coverage for primary CNS lymphoma

Effective DateJan 15, 2025

Next Review DateJan 15, 2026

Key ActionObtain prior authorization that documents guideline or specialty society support and prior therapies when requesting HSCT for relapsed or high-risk solid tumors.

SourceLink

POLICY UPDATE CHANGES

Revised policy statements for Central Nervous System (CNS) Tumors, Germ Cell Tumors, and Adult - Other.

Primary CNS lymphoma removed from the policy.

20document pages (approx.)

≥3tandem/autologous HSCT permitted

standardpediatric/neuroblastoma standard

manyadult solid tumors not MN

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for HSCT in Solid Tumors

Central Nervous System (CNS) Tumors - HSCT

Coverage stance for HSCT in CNS tumors

CNS HSCT coverage: All allogeneic transplantations must be from an appropriately-matched HLA donor.

Autologous HSCT considered medically necessary for: supratentorial primitive neuroectodermal tumor (PNET); medulloblastoma.

Autologous HSCT considered not medically necessary for: anaplastic glioma; astrocytoma; ependymoma; glioblastoma; meningioma; oligodendroglioma; primary spinal cord tumors.

Allogeneic HSCT stance: Allogeneic HSCT is considered not medically necessary for the treatment of central nervous system tumors.

Ewing Family of Tumors - HSCT

Coverage for Ewing family tumors

Donor matching: All allogeneic transplantations must be from an appropriately-matched HLA donor.

Autologous HSCT is considered medically necessary for the treatment of relapsed or progressive Ewing family of tumors.

Germ Cell Tumors (testicular/ovarian) - HSCT

Coverage for germ cell tumors

Donor matching: All allogeneic transplantations must be from an appropriately-matched HLA donor.

Autologous HSCT medically necessary: Single or tandem autologous HSCT is considered medically necessary for relapsed or refractory testicular and ovarian germ cell tumors.

Tandem/number: Up to three autologous HSCT is considered medically necessary as second-line therapy for metastatic germ cell tumors.

Not medically necessary: Autologous HSCT as front-line therapy for testicular cancer; allogeneic HSCT for testicular cancer.

Neuroblastoma - HSCT

Pediatric neuroblastoma HSCT coverage

Donor matching: All allogeneic transplantations must be from an appropriately-matched HLA donor.

Autologous HSCT medically necessary: Autologous HSCT is considered medically necessary for the treatment of high-risk neuroblastoma.

Allogeneic HSCT medically necessary when not candidate for autologous: Allogeneic HSCT is considered medically necessary for high-risk neuroblastoma when the individual is not a candidate for autologous HSCT.

Tandem limit: A maximum of three tandem autologous HSCTs is considered.

Retinoblastoma and Wilms Tumor - HSCT

Pediatric ocular and renal tumor HSCT coverage

Retinoblastoma: Autologous HSCT is considered medically necessary for the treatment of retinoblastoma.

Wilms tumor: Autologous HSCT is considered medically necessary for the treatment of relapsed Wilms tumor.

Donor matching: All allogeneic transplantations must be from an appropriately-matched HLA donor.

Adult Other Solid Tumors - HSCT Not Medically Necessary

Adult solid tumor indications where HSCT is considered not medically necessary

Not medically necessary list: HSCT for adult cancers of the bile duct; breast; cervix; colon and rectum; esophagus; gallbladder; lung; nasopharynx; pancreas; paranasal sinus; prostate; stomach; thymus; thyroid; uterus; epithelial ovarian cancer; melanoma; renal cell carcinoma; soft tissue sarcoma.

Donor matching note: All allogeneic transplantations must be from an appropriately-matched HLA donor where applicable.

Guideline‑supported indications

Covered when guideline-supported and patient meets tumor‑specific conditions:

Ewing sarcoma: High‑dose therapy followed by stem cell transplant has been associated with potential survival benefit in selected patients with Ewing sarcoma, including relapsed/refractory disease; consider for high‑risk or relapsed patients per ASTCT/NCCN guidance.

Osteosarcoma: HDT/SCT has been evaluated in locally advanced, metastatic, or relapsed osteosarcoma but efficacy in high‑risk disease remains to be determined in randomized studies; may be considered in select relapsed cases per guidelines.

Germ cell tumors: For relapsed or refractory malignant germ cell tumors, high‑dose chemotherapy with autologous stem cell rescue is a guideline‑recognized option and referral to a tertiary center for transplant consultation is recommended; considered potentially curative in select patients.

CNS tumors (medulloblastoma, select recurrent embryonal tumors):

Indications with evidence against use

Ineffective or unsupported indications: High‑dose, marrow‑ablative chemotherapy with autologous stem cell rescue has been shown to be ineffective in extending survival for children with DIPG and there is no evidence of benefit for residual, non‑disseminated ependymoma; these indications are not supported by NCI PDQ statements.

Covered when guidelines support HSCT as option or standard

Guideline‑based coverage contexts described in excerpts

Germ cell tumors (relapsed/metastatic): For relapsed seminoma or early relapses (within 2 years) of nonseminoma, options include enrollment in a clinical trial (preferred), conventional‑dose chemotherapy, or high‑dose chemotherapy with SCT; both conventional‑dose and high‑dose regimens are preferred when chemotherapy is given.category 2B

Neuroblastoma (high‑risk): High‑risk neuroblastoma standard consolidation includes high‑dose chemotherapy with autologous stem cell rescue and consolidative radiotherapy; tandem myeloablative therapy and HSCT are part of standard regimens.standard of care

Wilms tumor (relapse/high‑risk): For high‑risk and very high‑risk relapsed Wilms tumor, treatment options include chemotherapy, surgery, radiation, and HSCT; high‑dose chemotherapy followed by autologous HSCT has been utilized for recurrent high‑risk patients.

Coverage by tumor type / evidence summary

Coverage stance varies by diagnosis and evidence:

Neuroblastoma - Autologous HSCT: Autologous HSCT is a standard treatment option for individuals classified as having high-risk neuroblastoma; improved survival demonstrated in randomized trials.

Germ cell tumors - Autologous HSCT: Single or tandem high-dose chemotherapy with autologous HSCT is considered an acceptable therapy for refractory or relapsed testicular and ovarian germ cell tumors; for metastatic germ-cell tumors, three cycles of high-dose chemotherapy each followed by HSCT is an appropriate second-line option.

Retinoblastoma - Autologous HSCT: Autologous HSCT has suggested safety and effectiveness in prospective case series for retinoblastoma with disease-free survival reported and vision preservation in small series.

Soft tissue sarcoma - Autologous/Allogeneic HSCT: Registry and literature data do not support routine use of autologous HSCT for soft tissue sarcoma; ASCT should not be performed in routine clinical practice.

Medically Necessary Transplant Services

Considered medically necessary when criteria in the applicable policy statements are met:

General requirement: Services represented by the enumerated CPT/HCPCS codes are considered medically necessary when the applicable clinical criteria in the policy are met and when aligned with current NCD/LCD determinations.

Evidence summaries for select pediatric and solid tumor indications

Supportive literature findings summarized in policy:

Retinoblastoma evidence: Prospective case series and retrospective studies suggest autologous HSCT can be safe and effective in retinoblastoma with reported disease-free survival and vision preservation; treatment-related mortality was zero in cited studies.

Soft tissue sarcoma evidence: EBMT registry analysis (n=338) reported median PFS 8.3 months and OS 19.8 months with 5-year PFS 13% and OS 25%; authors concluded ASCT should not be performed in routine clinical practice for STS.

Wilms tumor evidence: Results are mixed; some data suggest survival benefit with high-dose chemotherapy and autologous HSCT for relapsed Wilms tumor.

Autologous hematopoietic stem cell transplantation (HSCT) is identified in this policy as a medically necessary option for select pediatric solid tumors, including high‑risk neuroblastoma and retinoblastoma, with a stated maximum of three tandem autologous HSCTs where applicable. All allogeneic transplantations must be from an appropriately‑matched HLA donor. For adults, the policy lists many solid tumor types for which HSCT is considered not medically necessary (see tumor‑specific listings).

The policy explicitly states that allogeneic HSCT is considered not medically necessary for the treatment of central nervous system (CNS) tumors. This stance aligns with cited evidence that high‑dose, marrow‑ablative approaches have not demonstrated survival benefit for certain pediatric CNS diagnoses such as diffuse intrinsic pontine glioma (DIPG).

The policy cites NCI PDQ conclusions that high‑dose, marrow‑ablative chemotherapy with autologous hematopoietic stem cell rescue has been shown to be ineffective in extending survival for children with DIPG, and therefore this approach is not supported for DIPG.

The policy notes that the absence of reference to stem cell transplant in relevant NCCN guidance (for example, NCCN sections for epithelial ovarian cancer and kidney cancer) indicates a lack of guideline support for HSCT in those tumor types and is reflected in the policy's noncoverage conclusions for those indications.

NCCN Soft Tissue Sarcoma guidance does not mention stem cell transplant; the policy therefore treats HSCT for most soft tissue sarcoma indications as lacking guideline support and not recommended for routine practice.

As part of the annual review, primary CNS lymphoma was removed from the policy. Operationally, providers should no longer rely on this policy for transplant coverage decisions regarding primary CNS lymphoma.

The policy lists a set of adult solid tumors for which HSCT is considered not medically necessary; examples include cancers of the bile duct, breast, cervix, colon and rectum, esophagus, gallbladder, lung, nasopharynx, pancreas, paranasal sinus, prostate, stomach, thymus, thyroid, uterus, epithelial ovarian cancer, melanoma, renal cell carcinoma, and soft tissue sarcoma.

For pediatric diffuse intrinsic pontine glioma (DIPG), the policy states that the use of high‑dose, marrow‑ablative chemotherapy with autologous stem cell rescue is not medically necessary because available evidence does not show a survival benefit.

The policy references ASTCT categorizations and notes that several pediatric and adult tumor types are labeled with 'N' (not generally recommended) or 'D' (developmental), indicating HSCT is not generally recommended or remains investigational/developmental for those indications.

ASTCT and NCI PDQ summaries cited in the policy indicate that high‑dose chemotherapy with autologous or allogeneic stem cell rescue has been evaluated in a limited number of patients with rhabdomyosarcoma and, overall, has failed to demonstrate improved outcomes; routine use is not supported.

The European Society for Blood and Marrow Transplantation (EBMT) registry analysis summarized in the policy reviewed 338 soft‑tissue sarcoma patients after autologous stem cell transplantation and concluded that ASCT should not be performed in routine clinical practice for soft tissue sarcoma, reflecting insufficient evidence of routine benefit.

Regimens and Situations Where HSCT May Be Used

Regimen	Indication / Line of Therapy	Coverage Status
High-dose carboplatin plus etoposide followed by autologous stem cell transplant	Second-line and subsequent therapy for metastatic germ cell tumors; relapsed/refractory malignant germ cell disease	Covered
Paclitaxel plus ifosfamide followed by high-dose carboplatin plus etoposide with stem cell support	Second-line and subsequent therapy for metastatic germ cell tumors; relapsed/refractory malignant germ cell disease	Covered
Conventional-dose regimens TIP (paclitaxel, ifosfamide, cisplatin) or VeIP (vinblastine, ifosfamide, cisplatin)	Second-line options for relapsed seminoma or early relapses of nonseminoma; considered conventional-dose chemotherapy option	Covered

Regimen/Approach	Indication	Coverage Status
High-dose systemic therapy with autologous stem cell reinfusion	Recurrent medulloblastoma or recurrence in patients without residual disease after re-induction systemic therapy or re-resection	Covered (feasible/select patients)

Regimen/Approach	Indication	Coverage Status
High-dose marrow-ablative chemotherapy with autologous hematopoietic stem cell rescue	Diffuse intrinsic pontine glioma (DIPG)	Not covered (ineffective/no evidence of benefit)
High-dose marrow-ablative chemotherapy with autologous hematopoietic stem cell rescue	Residual, non-disseminated ependymoma	Not covered (no evidence of benefit)

Regimen	Indication / Line of Therapy	Coverage Status
Conventional-dose TIP or VeIP	Second-line relapsed germ cell tumors; conventional-dose chemotherapy option	Covered
High-dose carboplatin plus etoposide followed by autologous stem cell transplant	Second-line relapsed germ cell tumors; high-dose chemotherapy option	Covered
Paclitaxel plus ifosfamide followed by high-dose carboplatin plus etoposide with stem cell support	Second-line relapsed germ cell tumors; high-dose chemotherapy option	Covered

Therapeutic Category / Agents	Indication	Coverage Status
Chemotherapy combined with immunotherapy (including anti-GD2 immunotherapy)	Recurrent or refractory neuroblastoma	Informational/covered when guideline-supported
Novel targeted agents (ALK inhibitors, WEE1 inhibitors); bevacizumab	Recurrent or refractory neuroblastoma, when molecular targets appropriate	Informational/covered when guideline-supported
Phase I/II chemotherapy combinations (topotecan + cyclophosphamide or etoposide; temozolomide + irinotecan)	Recurrent or refractory neuroblastoma (investigational/early-phase combinations)	Informational/coverage dependent on evidence/clinical context

Role	Indication / Timing	Coverage Status
Autologous hematopoietic stem cell transplantation (ASCT) as consolidation	Following induction/consolidation therapy for high-risk neuroblastoma	Covered (standard of care)

Strategy	Indication / Line of Therapy	Coverage Status
Single or tandem high-dose chemotherapy with autologous HSCT	Relapsed/refractory germ cell tumors; tandem or single procedures used per clinical scenario	Covered
Three cycles of high-dose chemotherapy, each followed by HSCT	Metastatic germ-cell tumors as a second-line approach	Covered

Approach	Indication	Coverage Status
Autologous HSCT	Soft tissue sarcoma (routine clinical practice)	Not covered (not recommended for routine practice)

Preparative Platform / Regimen Note	Evidence Summary / Patient Selection	Coverage Status
Melphalan-based preparative regimens and other high-dose chemotherapy platforms	Registry and retrospective analyses suggest selective benefit in younger patients and those with better remission status; evidence does not support routine use for some histologies (e.g., STS)	Mixed / selective coverage (benefit in select patients; not routine)

Coding and Billing Information

Covered CPT/HCPCS CodesCPT|HCPCSCovered

38205	Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection; allogeneic.
38206	Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection; autologous.
38207	Transplant preparation of hematopoietic progenitor cells; cryopreservation and storage.
38208	Transplant preparation of hematopoietic progenitor cells; thawing of previously frozen harvest, without washing, per donor.
38209	Transplant preparation of hematopoietic progenitor cells; thawing of previously frozen harvest, with washing, per donor.
38210	Transplant preparation of hematopoietic progenitor cells; specific cell depletion within harvest, T-cell depletion.
38211	Transplant preparation of hematopoietic progenitor cells; tumor cell depletion.
38212	Transplant preparation of hematopoietic progenitor cells; red blood cell removal.
38213	Transplant preparation of hematopoietic progenitor cells; platelet depletion.
38214	Transplant preparation of hematopoietic progenitor cells; plasma (volume) depletion.

1–10 of 19

1/2

Cardiac ejection fraction threshold

Cardiac ejection fraction thresholdEjection fraction less than 35% is a relative contraindication to HSCT

Source contextListed as a relative contraindication under transplant selection criteria

ApplicabilityUsed in pre-transplant cardiac assessment to determine transplant eligibility

Bilirubin threshold

Bilirubin thresholdTotal bilirubin greater than 2.0 mg/dL is a relative contraindication to HSCT

Associated liver labsElevated transaminases >2x normal are listed alongside bilirubin as hepatic contraindications

Provider Requirements and Operational Guidance

Prior Authorization

Prior authorization and plan-specific coverage

Refer to the member's specific benefit plan for coverage details and submit prior authorization requests per payer rules before scheduling HSCT services. Coverage varies by Cigna line of business and the member's plan document always controls when in conflict with this policy.

Verify member eligibility and benefits (Group Service Agreement/EOC/Certificate/SPD)
Submit prior authorization per Cigna procedures and include relevant clinical documentation

Prior Authorization

Prior authorization likely needed for HSCT in relapsed/high‑risk solid tumors

Prior authorization is typically required for hematopoietic stem cell transplantation (HSCT) when used for relapsed or high‑risk solid tumors (e.g., relapsed medulloblastoma, relapsed Ewing family tumors, relapsed/refractory germ cell tumors, high‑risk neuroblastoma). Ensure requests reference guideline-supported indications.

Indications commonly requiring prior authorization: relapsed medulloblastoma, relapsed Ewing tumors, relapsed/refractory germ cell tumors, high‑risk neuroblastoma

Key Definitions

Hematopoietic stem cell transplantation (HSCT) is a procedure that replaces blood‑forming stem cells destroyed by high‑dose chemotherapy or radiation. HSCT may be autologous (the patient's own cells are harvested, stored, and re‑infused) or allogeneic (stem cells are obtained from a donor), and is used selectively in certain pediatric cancers and a limited set of solid tumor scenarios where guideline or evidence support exists.

Autologous transplant — definition

DefinitionAutologous transplant: a patient's own hematopoietic stem cells are harvested, stored (frozen), and re-infused after high-dose chemotherapy or radiation

Procedure noteHarvested cells are thawed and returned to the individual after conditioning

Typical useUsed to restore hematopoiesis after myeloablative therapy for selected malignancies

Allogeneic transplant — definition

Definition

Line of Therapy Contexts (First-line, Second-line, Salvage)

second-line

Line-of-therapy mapping for HSCT requests

second-line: Up to three autologous HSCT is considered medically necessary as second-line therapy for metastatic germ cell tumors.

[[chunk 5]]

relapsed: Autologous HSCT is considered medically necessary for relapsed or progressive Ewing family of tumors.

[[chunk 5]]

first-line: Autologous HSCT is standard front-line consolidation for high‑risk neuroblastoma as part of induction/consolidation protocols.

[[chunk 48]]

relapsed

Biomarker / Molecular Requirements

ALK — biomarker requirement entry

ALK biomarker requirementALK mutation testing is listed as a novel therapy consideration for patients with ALK mutations in neuroblastoma (informational biomarker requirement)

Context of useALK inhibitors are noted among novel therapies in neuroblastoma guidance and cited as relevant to treatment selection

Documentation implicationPresence of ALK mutation may guide use of ALK inhibitors as part of salvage/novel therapy approaches in recurrent/refractory neuroblastoma

Policy Revision History

2025-01-15annual_reviewLatest

Revised policy statements for Central Nervous System (CNS) Tumors, Germ Cell Tumors, and Adult - Other; removed primary CNS lymphoma from the policy.

2024-01-15annual_review

Annual review entry recorded in document revision history.

Policy Summary

PayerCigna

PolicyHematopoietic Stem Cell Transplantation (HSCT) for Solid Tumors

Policy CodePolicy 0534

Change TypeRevisions and removal of coverage for primary CNS lymphoma

Effective DateJan 15, 2025

Next Review DateJan 15, 2026

Key ActionObtain prior authorization that documents guideline or specialty society support and prior therapies when requesting HSCT for relapsed or high-risk solid tumors.

SourceLink

On This Page

High‑dose chemotherapy with autologous stem cell reinfusion may be considered in recurrent medulloblastoma or for patients without residual disease after re‑induction chemotherapy per NCCN; utility is limited in many pediatric high‑grade gliomas and DIPG where evidence shows no survival benefit.

Retinoblastoma (extraocular/metastatic): Options include systemic chemotherapy followed by myeloablative chemotherapy and stem cell rescue with or without radiation for extraocular or synchronous trilateral disease; systemic chemotherapy followed by myeloablative chemotherapy with stem cell rescue and radiation for extracranial metastatic disease is noted.

Rhabdomyosarcoma - HSCT: High-dose chemotherapy with autologous or allogeneic stem cell rescue has been evaluated in a limited number of patients with rhabdomyosarcoma and has failed to improve outcomes in available data.

Allogeneic HSCT for adult solid tumors: Available data do not suggest an enduring benefit of allogeneic HSCT for many adult solid tumor indications; significant rates of graft failure, GVHD and treatment-related mortality have been reported.

Exception noteHepatic abnormalities may be excepted if related to underlying disease (per source)

Transaminases threshold

Transaminases thresholdTransaminases greater than two times normal are a relative contraindication to HSCT

ContextListed with bilirubin as indicators of poor liver function in pre-transplant evaluation

Clinical implicationElevated transaminases may preclude HSCT unless abnormalities are disease-related

Creatinine clearance threshold

Creatinine clearance thresholdCreatinine clearance less than 50 mL/min is a relative contraindication to HSCT (not applicable for most autologous transplants)

ApplicabilityUsed to assess renal function prior to transplant; special consideration for autologous transplants noted

Clinical impactRenal impairment below this threshold may contraindicate transplant or require modified approach

Diffusion capacity threshold

Diffusion capacity thresholdPulmonary diffusion capacity less than 50% of predicted is a relative contraindication to HSCT

Pulmonary assessmentDiffusion capacity used in pre-transplant pulmonary function testing to assess transplant risk

Related risksPoor pulmonary function increases transplant morbidity and mortality risk

Karnofsky / ECOG functional status thresholds

Karnofsky / ECOG thresholdKarnofsky performance status less than 60% and/or ECOG performance status greater than 2 are relative contraindications to HSCT

Use in selectionPerformance status thresholds inform candidacy for transplant and expected outcomes

Assessment frequencyPerformance status should be evaluated as part of pre-transplant eligibility assessment

Code validity — providers must use active (not deleted) codes at time of service

Code validity requirementProviders must use codes that are active and not deleted at the time of service; deleted or inactive codes may not be eligible for reimbursement

Operational noteAMA and CMS code updates may occur more frequently than policy updates; confirm current code status before claim submission

Denial riskServices billed with non-active or deleted codes may be denied

Include prior lines of therapy and response to show relapsed or high‑risk status

Prior Authorization

Prior authorization for supported indications

Prior authorization should be obtained for supported indications where evidence or guidelines recommend HSCT (for example, high‑risk neuroblastoma, relapsed germ cell tumors, selected CNS embryonal tumors). Requests should cite specialty society or guideline recommendations.

Reference NCCN, ASBMT/ASTCT, or relevant NCI PDQ guidance in the authorization request
Document when HSCT is being used as second‑line or subsequent therapy per guideline language

Prior Authorization

Prior authorization for transplant-related codes

Prior authorization is required for services represented by transplant‑related CPT/HCPCS codes; services are payable only when the policy criteria for medical necessity are met.

Ensure prior authorization covers the specific procedure codes to be billed (see list of transplant/harvesting/preparation/infusion codes)
Reimbursement only when submitted services meet coverage criteria

Denial Risk

Coding mismatch denial risk

Services billed without an appropriate covered diagnosis or procedure code that meets the applicable Coverage Policy are at high risk for denial. Use the most appropriate and current codes as of the date of service.

Review coding against the policy's listed CPT/HCPCS codes before claim submission
Avoid billing transplant procedure codes when the clinical criteria are not met to reduce coding‑mismatch denials

Prior Authorization

No explicit authorization triggers provided — obtain authorization and document rationale

The excerpts do not provide a complete list of explicit prior authorization triggers for every indication. Providers should not assume automatic coverage — submit full prior authorization requests with supporting documentation for clinical review when HSCT is contemplated.

When in doubt, obtain prior authorization and include rationale and guideline citations
Clinical directors have discretion to make individual coverage determinations based on the submitted information

Note

Medicare coverage alignment

Coverage is subject to Medicare national and local coverage determinations. Failure to meet current Medicare NCD/LCD requirements may affect payment — verify Medicare rules when the member is Medicare‑eligible or when Medicare rules inform commercial coverage determinations.

Review applicable Medicare NCDs/LCDs (e.g., STEM CELL Transplantation NCD) for alignment with requested services
Note: Medicare policy should be checked for the most up‑to‑date determinations

Documentation Required

Coding and submission documentation

When requesting authorization and submitting claims, use appropriate procedure/diagnosis codes current as of the service date and include required supporting documentation. Claims will be reimbursed only when services meet the coverage criteria in the applicable policy statements.

Use the most appropriate CPT/HCPCS/ICD‑10 codes as of the service date
Include operative reports, transplant evaluation notes, and documentation of pre‑transplant workup

Documentation Required

Response and marker documentation

For germ cell tumors, document serial tumor markers (AFP, beta‑HCG) and clinical response. For patients who achieve a complete clinical response after chemotherapy, follow guideline recommendation to observe clinically every 2–4 months with AFP and beta‑HCG (if initially elevated) for 2 years.

Include baseline and follow‑up AFP and beta‑HCG levels in the authorization record when markers were initially elevated
Document schedule of planned post‑treatment marker surveillance for the first 2 years

Documentation Required

For patients achieving complete clinical response — documentation and surveillance

When a patient achieves a complete clinical response after conventional‑dose chemotherapy, document the response and planned observation strategy; if HSCT is being considered for recurrent disease, provide marker trends and evidence of recurrence or refractory disease.

Document imaging and physical exam findings that support complete clinical response
Show subsequent marker elevations or definitive recurrent disease when seeking HSCT for recurrence

Documentation Required